Advertisement
Screener

Humacyte, Inc. (HUMA) Stock Issued During Period, Value, Stock Options Exercised

2.8 / 5 stars · 68/120 Roast Me

Humacyte, Inc. Stock Issued During Period, Value, Stock Options Exercised

New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.

  • Humacyte, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $30.00K.
  • Humacyte, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $56.00K, a 2700.00% increase year-over-year.
  • Humacyte, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $495.00K, a 400.00% increase year-over-year.
  • Humacyte, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $787.00K, a 728.42% increase year-over-year.
  • Humacyte, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $61.00K, a 95.96% decline from fiscal 2024.
  • Humacyte, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $1.51M, a 166.96% increase from fiscal 2023.
  • Humacyte, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $566.00K, a 5.79% increase from fiscal 2022.
  • Humacyte, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $535.00K, a 10.54% decline from fiscal 2021.
Period endStock Issued During Period, Value, Stock Options Exercised 3 monthStock Issued During Period, Value, Stock Options Exercised 12 month
2026-06-30$30.00K
10-Q · filed 2026-08-12
2025-12-31$61.00K
10-K · filed 2026-03-27
2025-03-31$56.00K
10-Q · filed 2026-08-12
2024-12-31$1.51M
10-K · filed 2026-03-27
2024-09-30$495.00K
10-Q · filed 2025-11-12
2024-06-30$787.00K
10-Q · filed 2025-11-12
2024-03-31$2.00K
10-Q · filed 2025-11-12
2023-12-31$566.00K
10-K · filed 2025-03-31
2023-09-30$99.00K
10-Q · filed 2024-11-08
2023-06-30$95.00K
10-Q · filed 2024-11-08
2023-03-31$119.00K
10-Q · filed 2024-11-08
2022-12-31$535.00K
10-K · filed 2024-03-28
2022-09-30$217.00K
10-Q · filed 2023-11-09
2022-06-30$11.00K
10-Q · filed 2023-11-09
2022-03-31$1.00K
10-Q · filed 2023-11-09
2021-12-31$598.00K
10-K · filed 2023-03-24
2021-09-30$360.00K
10-Q · filed 2022-11-10
2021-06-30$30.00K
10-Q · filed 2022-11-10
2021-03-31$206.00K
10-Q · filed 2022-11-10
2020-12-31$301.00K
10-K · filed 2022-03-29
2020-09-30$12.00K
10-Q · filed 2021-11-15
2020-06-30$48.00K
10-Q · filed 2021-11-15
2020-03-31$175.00K
10-Q · filed 2021-11-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63